Tumor necrosis factor alpha gene polymorphism in patients wiht essential hypertension
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Aim. To analyze the association between tumor necrosis factor-alpha gene –308 G/A polymorphism and essential arterial hypertension (EAH).
Material and methods. The study included 354 EAH patients and 295 age-matched healthy subjects. DNA was extracted from venous blood. Genotyping was performed using polymerase chain reaction followed by restriction amplicon analysis.
Results. TNFA -308*G/*G genotype frequency was significantly lower among EAH patients with stroke than in control group (60,98% vs 78,98%; p=0,015). EAH patients with TNFA -308 *G/*G genotype had lower stroke risk (OR=0,38; 95% CI: 0,21-0,83).
Conclusion. The results obtained suggest that TNFA gene -308G/A polymorphism is involved in stroke pathogenesis among EAH patients.
About the Authors
Y. R. TimashevaRussian Federation
T. R. Nasibullin
Russian Federation
A. N. Zakirova
Russian Federation
O. E. Mustafina
Russian Federation
References
1. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003; 361: 1629-41.
2. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=145500.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
4. Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Science 2005; 108: 205-13.
5. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-a and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53.
6. Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-a in postinfarction dysfunctional myocardium. Circulation 1999; 99: 1492-8.
7. WilsonAG, de Vries N, Pociot F, et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA, A1, B8 and DR3 alleles. J ExpMed 1993; 177: 557-60.
8. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
9. Johns M, Paulus-Thomas J. Purification of human genomic DNA from whole venous blood using proteinase K treatment fol-lowed by phenol-chloroform extraction. Annal Biochem 1989; 180: 276-8.
10. Keso T, Perola M, Laippala P et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 2001; 154: 691-7.
11. Bland JM, Altman DG. The odds ratio. Br Med J 2000; 320: 1468.
12. Mitchell SA, Grove J, Spurkland A, et al. Association of the tumour necrosis factor a - 308 but not the interleukin 10 - 627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001; 49: 288-94.
13. Rasmussen SK, Urhammer SA, Jensen JN, et al. O. The -238 and -308 G/A polymorphisms of the tumor necrosis factor D gene promotor are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. J Clin Endocrinol Metab 2000; 85: 1731-4.
14. Spriewald BM, Witzke O, Wassmuth R, et al. Distinct tumour necrosis factor a, interferon c, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener’s granulomatosis. Ann Rheum Dis 2005; 64: 457-61.
15. McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Research 2002; 62: 3369-72.
16. Louis R, Leyder E, Malaise M, et al. Lack of association between adult asthma and the tumour necrosis factor a-308 polymorphism gene. Eur Respir J 2000; 16: 604-8.
17. Tuglular S, Berthoux P, Berthoux F. Polymorphisms of the tumour necrosis factor a gene at position -308 and TNFa microsatellite in primary IgA nephropathy. Nephrol Dial Transpl 2003; 18: 724-31.
18. Caballero A, Bravo J, Nieto A, et al. TNFA promoter polymorphism and susceptibility to brucellosis. Clin Exp Immunol 2000; 121: 480-3.
19. Moukoko CE, El Wali N, Saeed OK, et al. No evidence for a major effect of tumor necrosis factor alpha gene polymorphisms in periportal fibrosis caused by Schistosoma mansoni infection. Infect Imm 2003; 71: 5456-60.
20. Corbett EL, Mozzato-Chamay N, Butterworth AE, et al. Polymorphisms in the tumor necrosis factor-a gene promoter may predispose to severe silicosis in black South African miners. Am J Respir Crit Care Med 2002; 165: 690-3.
21. Kubota T, McNamara DM, Wang JJ, et al. Effects of Tumor Necrosis Factor Gene Polymorphisms on Patients With Congestive Heart Failure. Circulation 1998; 97: 2499-501.
22. Um JY, Kim HM. Frequencies of the tumor necrosis factor gene polymorphisms in the Korean population. Hereditas 2003; 139: 184-8.
23. Funayama T, Ishikawa K, Ohtake Y, et al. Variants in optineurin gene and their association with tumor necrosis factor-a polymorphisms in Japanese patients with glaucoma. Invest Ophthalmol Vis Sci 2004; 45: 4359-67.
24. Pfeilschifter J, Koditz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23: 90-119.
25. Pausova Z, Deslauriers B, Gaudet D, et al. Role of tumor necrosis factor-Dgene locus in obesity and obesity-associated hypertension in French Canadians. Hypertension 2000; 36: 14-9.
26. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacology 2006; 147: 232- 40.
27. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med 2002; 8: 1363-8.
Review
For citations:
Timasheva Y.R., Nasibullin T.R., Zakirova A.N., Mustafina O.E. Tumor necrosis factor alpha gene polymorphism in patients wiht essential hypertension. Cardiovascular Therapy and Prevention. 2007;6(6):5-9. (In Russ.)
ISSN 2619-0125 (Online)